Changes in cell wall synthesis and ultrastructure during paradoxical growth effect of caspofungin on four different Candida species

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 1, 2011, Pages 302-310

  Bizerra, Fernando C ^a   Melo, Analy S A ^a   Katchburian, Eduardo ^a   Freymüller, Edna ^a   Straus, Anita H ^a   Takahashi, Hélio K ^a   Colombo, Arnaldo L ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 1,3 GLUCAN; CASPOFUNGIN; CHITIN;

ANTIBIOTIC SENSITIVITY; ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA; CANDIDA ALBICANS; CANDIDA ORTHOPSILOSIS; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CELL SURVIVAL; CELL ULTRASTRUCTURE; CELL WALL; ELECTRON MICROSCOPY; FLUORESCENCE MICROSCOPY; FUNGUS GROWTH; MICROBIAL FUEL CELL; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PARADOXICAL GROWTH; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; TRANSMISSION ELECTRON MICROSCOPY;

ANTIFUNGAL AGENTS; CANDIDA; CELL WALL; ECHINOCANDINS; MICROBIAL SENSITIVITY TESTS; MICROSCOPY, ATOMIC FORCE; MICROSCOPY, ELECTRON, TRANSMISSION; MICROSCOPY, FLUORESCENCE;

EID: 78650637704     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00633-10     Document Type: Article

References (38)

1. Balashov, S. V., S. Park, and D. S. Perlin. 2006. Assessing resistance to the echinocandin antifungal drug caspofungin in Candida albicans by profiling mutations in FKS1. Antimicrob. Agents Chemother. 50:2058-2063.
2. Barchiesi, F., E. Spreghini, S. Tomassetti, D. Arzeni, D. Giannini, and G. Scalise. 2005. Comparison of the fungicidal activities of caspofungin and amphotericin B against Candida glabrata. Antimicrob. Agents Chemother. 49:4989-4992.
3. Barchiesi, F., E. Spreghini, S. Tomassetti, A. Della Vittoria, D. Arzeni, E. Manso, and G. Scalise. 2006. Effects of caspofungin against Candida guilliermondii and Candida parapsilosis. Antimicrob. Agents Chemother. 50: 2719-2727.
4. Bizerra, F. C., C. V. Nakamura, C. de Poersch, T. I. Estivalet Svidzinski, R. M. Borsato Quesada, S. Goldenberg, M. A. Krieger, and S. F. Yamada-Ogatta. 2008. Characteristics of biofilm formation by Candida tropicalis and antifungal resistance. FEMS Yeast Res. 8:442-450.
5. Canton, E., J. Peman, M. Romero, A. Valentin, and M. Gobernado. 2007. The fungicidal activity and paradoxical effect of caspofungin against yeast. Influence of culture medium and incubation time. Rev. Esp. Quimioter. 20:433-441. (In Spanish.)
6. Chaffin, W. L., J. L. Lopez-Ribot, M. Casanova, D. Gozalbo, and J. P. Martinez. 1998. Cell wall and secreted proteins of Candida albicans: identification, function, and expression. Microbiol. Mol. Biol. Rev. 62:130-180.
7. Chamilos, G., R. E. Lewis, N. Albert, and D. P. Kontoyiannis. 2007. Paradoxical effect of echinocandins across Candida species in vitro: evidence for echinocandin-specific and Candida species-related differences. Antimicrob. Agents Chemother. 51:2257-2259.
8. Cleary, J. D., G. Garcia-Effron, S. W. Chapman, and D. S. Perlin. 2008. Reduced Candida glabrata susceptibility secondary to an FKS1 mutation developed during candidemia treatment. Antimicrob. Agents Chemother. 52:2263-2265.
9. Clemons, K. V., M. Espiritu, R. Parmar, and D. A. Stevens. 2006. Assessment of the paradoxical effect of caspofungin in therapy of candidiasis. Antimicrob. Agents Chemother. 50:1293-1297.
10. Clinical and Laboratory Standards Institute (CLSI). 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts, third ed. Approved standard, M27-A3. CLSI, Wayne, PA.
11. da Matta, D. A., L. P. de Almeida, A. M. Machado, A. C. Azevedo, E. J. Kusano, N. F. Travassos, R. Salomao, and A. L. Colombo. 2007. Antifungal susceptibility of 1000 Candida bloodstream isolates to 5 antifungal drugs: results of a multicenter study conducted in Sao Paulo, Brazil, 1995-2003. Diagn. Microbiol. Infect. Dis. 57:399-404.
12. Denning, D. W. 2003. Echinocandin antifungal drugs. Lancet 362:1142-1151.
13. Douglas, C. M. 2001. Fungal beta(1,3)-D-glucan synthesis. Med. Mycol. 39(Suppl. 1):55-66.
14. Dubois, M., K. Gilles, J. K. Hamilton, P. A. Rebers, and F. Smith. 1951. A colorimetric method for the determination of sugars. Nature 168:167.
15. Fleischhacker, M., C. Radecke, B. Schulz, and M. Ruhnke. 2008. Paradoxical growth effects of the echinocandins caspofungin and micafungin, but not of anidulafungin, on clinical isolates of Candida albicans and C. dubliniensis. Eur. J. Clin. Microbiol. Infect. Dis. 27:127-131.
16. Garcia-Effron, G., D. P. Kontoyiannis, R. E. Lewis, and D. S. Perlin. 2008. Caspofungin-resistant Candida tropicalis strains causing breakthrough fungemia in patients at high risk for hematologic malignancies. Antimicrob. Agents Chemother. 52:4181-4183.
17. Garcia-Effron, G., S. Park, and D. S. Perlin. 2009. Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. Antimicrob. Agents Chemother. 53:112-122.
18. Goncalves, S. S., C. S. Amorim, M. Nucci, A. C. Padovan, M. R. Briones, A. S. Melo, and A. L. Colombo. 2010. Prevalence rates and antifungal susceptibility profiles of the Candida parapsilosis species complex: results from a nationwide surveillance of candidaemia in Brazil. Clin. Microbiol. Infect. 16:885-887.
19. Kahn, J. N., G. Garcia-Effron, M. J. Hsu, S. Park, K. A. Marr, and D. S. Perlin. 2007. Acquired echinocandin resistance in a Candida krusei isolate due to modification of glucan synthase. Antimicrob. Agents Chemother. 51:1876-1878.
20. Letscher-Bru, V., and R. Herbrecht. 2003. Caspofungin: the first representative of a new antifungal class. J. Antimicrob. Chemother. 51:513-521.
21. Marine, M., F. J. Pastor, I. H. Sahand, J. Ponton, G. Quindos, and J. Guarro. 2009. Paradoxical growth of Candida dubliniensis does not preclude in vivo response to echinocandin therapy. Antimicrob. Agents Chemother. 53:5297-5299.
22. Melo, A. S., A. L. Colombo, and B. A. Arthington-Skaggs. 2007. Paradoxical growth effect of caspofungin observed on biofilms and planktonic cells of five different Candida species. Antimicrob. Agents Chemother. 51:3081-3088.
23. Messer, S. A., D. J. Diekema, L. Boyken, S. Tendolkar, R. J. Hollis, and M. A. Pfaller. 2006. Activities of micafungin against 315 invasive clinical isolates of fluconazole-resistant Candida spp. J. Clin. Microbiol. 44:324-326.
24. Morgan, W. T., and L. A. Elson. 1934. A colorimetric method for the determination of N-acetylglucosamine and N-acetylchrondrosamine. Biochem. J. 28:988-995.
25. 2+ signalling pathways co-ordinately regulate chitin synthesis in Candida albicans. Mol. Microbiol. 63:1399-1413.
26. Nett, J., L. Lincoln, K. Marchillo, R. Massey, K. Holoyda, B. Hoff, M. VanHandel, and D. Andes. 2007. Putative role of beta-1,3 glucans in Candida albicans biofilm resistance. Antimicrob. Agents Chemother. 51:510-520.
27. Nishiyama, Y., K. Uchida, and H. Yamaguchi. 2002. Morphological changes of Candida albicans induced by micafungin (FK463), a water-soluble echinocandin-like lipopeptide. J. Electron Microsc. (Tokyo) 51:247-255.
28. Pappas, P. G., C. M. Rotstein, R. F. Betts, M. Nucci, D. Talwar, J. J. De Waele, J. A. Vazquez, B. F. Dupont, D. L. Horn, L. Ostrosky-Zeichner, A. C. Reboli, B. Suh, R. Digumarti, C. Wu, L. L. Kovanda, L. J. Arnold, and D. N. Buell. 2007. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin. Infect. Dis. 45:883-893.
29. Pfaller, M. A., L. Boyken, R. J. Hollis, J. Kroeger, S. A. Messer, S. Tendolkar, and D. J. Diekema. 2008. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J. Clin. Microbiol. 46:150-156.
30. Pfaller, M. A., D. J. Diekema, D. L. Gibbs, V. A. Newell, K. P. Ng, A. Colombo, J. Finquelievich, R. Barnes, and J. Wadula. 2008. Geographic and temporal trends in isolation and antifungal susceptibility of Candida parapsilosis: a global assessment from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005. J. Clin. Microbiol. 46:842-849.
31. Pfaller, M. A., S. A. Messer, L. Boyken, C. Rice, S. Tendolkar, R. J. Hollis, and D. J. Diekema. 2003. Caspofungin activity against clinical isolates of fluconazole-resistant Candida. J. Clin. Microbiol. 41:5729-5731.
32. Popolo, L., D. Gilardelli, P. Bonfante, and M. Vai. 1997. Increase in chitin as an essential response to defects in assembly of cell wall polymers in the ggp1delta mutant of Saccharomyces cerevisiae. J. Bacteriol. 179:463-469.
33. Soczo, G., G. Kardos, I. Varga, B. Kelentey, R. Gesztelyi, and L. Majoros. 2007. In vitro study of Candida tropicalis isolates exhibiting paradoxical growth in the presence of high concentrations of caspofungin. Antimicrob. Agents Chemother. 51:4474-4476.
34. Stevens, D. A., M. Espiritu, and R. Parmar. 2004. Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations. Antimicrob. Agents Chemother. 48:3407-3411.
35. Stevens, D. A., M. Ichinomiya, Y. Koshi, and H. Horiuchi. 2006. Escape of Candida from caspofungin inhibition at concentrations above the MIC (paradoxical effect) accomplished by increased cell wall chitin; evidence for beta-1,6-glucan synthesis inhibition by caspofungin. Antimicrob. Agents Chemother. 50:3160-3161.
36. Walker, L. A., C. A. Munro, I. de Bruijn, M. D. Lenardon, A. McKinnon, and N. A. Gow. 2008. Stimulation of chitin synthesis rescues Candida albicans from echinocandins. PLoS Pathog. 4:e1000040.
37. Wiederhold, N. P. 2007. Attenuation of echinocandin activity at elevated concentrations: a review of the paradoxical effect. Curr. Opin. Infect. Dis. 20:574-578.
38. Wiederhold, N. P., D. P. Kontoyiannis, R. A. Prince, and R. E. Lewis. 2005. Attenuation of the activity of caspofungin at high concentrations against Candida albicans: possible role of cell wall integrity and calcineurin pathways. Antimicrob. Agents Chemother. 49:5146-5148.